SELLAS Life Sciences (SLS) Receivables - Other (2012 - 2017)

SELLAS Life Sciences' (SLS) quarterly Receivables - Other came in at $500000.0 in Q3 2017, up 102.5% on a QoQ basis from -$20.0 million in Q1 2016.

SELLAS Life Sciences (SLS) Receivables - Other (2012 - 2017) Analysis & Trends

SELLAS Life Sciences (SLS) has 4 years of Receivables - Other data on file, last reported at $500000.0 in Q3 2017.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $500000.0 in Q3 2017; TTM through Sep 2017 was $500000.0, a N/A change from a year earlier, with the FY2016 full-year figure at -$21.7 million, down 200.0% from the prior year.
Receivables - Other for Q3 2017 stood at $500000.0, up from -$20.0 million in the prior quarter.
Over the last five years, Receivables - Other for SLS reached as high as $21.7 million in Q4 2015 and fell as low as -$20.0 million in Q1 2016.
Historically, Receivables - Other has averaged $733333.3 across 3 years, with a median of $500000.0 in 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	SELLAS Life Sciences	3.23 Mn	3.23 Mn	-

Download Data